Business
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/77b164c0949222ee521200a66eb4d9c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q67y7O29DKf2XCpStv5D9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/77b164c0949222ee521200a66eb4d9c0","width":480,"height":217}},"lazy":false},{"type":"text","content":"WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint of pulmonary vascular resistance (PVR) compared to placebo, improving the ability of blood to transition through the lungs to the heart","length":246,"tagName":"p","attribs":{}},{"type":"text","content":"These data support proof-of-concept to inform Phase 3 development for WINREVAIR in this population","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., November 18, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ (sotatercept-csrk) in adults for the treatment of combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary vascular resistance (PVR) from baseline at 24 weeks compared to placebo. Based on a preliminary assessment, the safety profile observed in the CADENCE study was generally consistent with the known safety profile for WINREVAIR.","length":738,"tagName":"p"},{"type":"text","content":""In this study, WINREVAIR improved pulmonary vascular resistance, an important hemodynamic measurement related to cardiac and pulmonary blood vessel function that has the potential to translate into improved outcomes for patients with combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction," said Dr. Mahesh Patel, vice president, global clinical development, Merck Research Laboratories. "The CADENCE trial was designed as a proof-of-concept study to evaluate the pharmacological activity of WINREVAIR in a new patient ...